NCT06687070 2025-02-26
APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
Ascentage Pharma Group Inc.
Phase 1 Recruiting
Ascentage Pharma Group Inc.
Shanghai Jiaolian Drug Research and Development Co., Ltd
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.